Cogent Biosciences, Inc.

NASDAQ:COGT

Biotechnology

Healthcare
$27.81 +2.60%

+$0.88 today

Market cap
$4.84B
Beta
0.35
P/E (TTM)
-6.6
EPS (TTM)
-$5.26
52W Low $6.92High $43.73

Volume 2.71M

Average 2.15M

COGT Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Cogent Biosciences, Inc.NASDAQ: COGT

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents rises 42.0% from a year ago

Cash & equivalents stood at $181.17M at the end of Q2 FY2026, up 42.0% from a year earlier and down 24.9% from the prior quarter. Over 3 fiscal years it compounded at +30.7% a year.

Context

  • Cash & equivalents amounted to 21.7% of total assets at the end of Q2 FY2026, down 24.7 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +42.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$181.17M-24.9% QoQ
Last fiscal yearDec 2025
$312.01M+217.8% YoY
Year agoJun 2025
$127.6M+42.0% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+42.0%——
1 year+217.8%——
3-year CAGR+30.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
312.01M USD
Year-over-year change
+217.8%
4-year CAGR
+9.2%

Cash & Equivalents vs competitors

How COGT compares with its peers on the latest reported figures

  • COGT's Jun 2026 cash & equivalents of $181.17M is the 4th highest of the 10 companies compared; the peer median is $150M.
  • Its year-over-year change of +42.0% is the 4th highest of 10, against a peer median of +21.2%.
  • Cash & equivalents amounts to 21.7% of total assets for COGT, versus a peer median of 17.8%.
COGT Competitors Peer median
Cash & Equivalents for COGT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
INCYIncyte CorporationJun 2026$3.98B +103.7%+1.6%50.6%
NRIXNurix Therapeutics, Inc.Aug 2026$720.24M +818.2%+56.5%60.3%
MAZEMaze Therapeutics, Inc.Mar 2026$198.77M -32.5%+23.7%47.4%
COGTCogent Biosciences, Inc.Jun 2026$181.17M +42.0%+30.7%21.7%
IDYAIDEAYA Biosciences, Inc.Mar 2026$157.52M +21.2%+18.0%15.3%
RCUSArcus Biosciences, Inc.Jun 2026$150M -39.5%+2.5%16.2%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$130.89M -15.0%+22.0%27.7%
TNGXTango Therapeutics, Inc.Sep 2026$86.84M +48.8%+23.3%8.4%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$62.1M +24.5%-34.7%17.8%
KURAKura Oncology, Inc.Mar 2026$39.08M -23.8%+42.2%6.0%
Peer median (excluding COGT) $150M+21.2%+22.0%17.8%

Competitors are the stored peer set for COGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents219.68M139.89M53.23M98.17M312.01M
Short-term Investments0119.39M212.48M188.91M588.75M
Net Receivables00000
Inventory00000
Other Current Assets01.26M5.06M9.4M9.59M
Total Current Assets222.63M264.97M270.77M296.47M910.36M
Property, Plant & Equipment (Net)4.48M31.1M30.34M26.56M23.54M
Goodwill00000
Intangible Assets00000
Long-term Investments1.26M07.46M00
Tax Assets00000
Other Non-current Assets3.73M4.75M4.86M4.86M3.72M
Total Non-current Assets9.46M35.84M42.67M31.43M27.25M
Total Assets232.09M300.81M313.44M327.9M937.61M
Account Payables3.48M5.84M10.66M12.01M9.5M
Short-term Debt00001.55M
Tax Payables00000
Deferred Revenue3.06M1.7M000
Other Current Liabilities3.62M6.47M10.32M12.63M52.9M
Total Current Liabilities17.08M26.85M38.17M55.71M63.95M
Long-term Debt0000237.25M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0000(14.32M)
Total Non-current Liabilities831K18.23M17.47M15.9M237.28M
Total Liabilities17.91M45.08M55.64M71.61M301.24M
Common Stock44K70K86K110K161K
Retained Earnings(270.97M)(411.21M)(603.62M)(859.48M)(1.19B)
Accumulated OCI(0)(104K)246K447K355K
Other Stockholders Equity00000
Minority Interest00000
Total Equity214.18M255.74M257.8M256.29M636.37M
Total Debt3.16M19.65M18.85M17.47M253.15M
Net Debt(216.53M)(120.24M)(34.38M)(80.7M)(58.86M)

Cogent Biosciences, Inc.

NASDAQ:COGT

Intrinsic Alpha fair value

Locked

Current Price

$27.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.